FeesSafety
Pluang+

Hims & Hers launches five new compounded peptides for longevity amid FDA approval gaps and safety debates

Others
18 Nov 2026, 16:02 WIB
CNBC
View Source
Neutral
Hims & Hers launches five new compounded peptides for longevity amid FDA approval gaps and safety debates

Hims & Hers Health has introduced five new compounded peptide and longevity treatments in the U.S. through its Peptides+ platform, including sermorelin, glutathione, NAD+, vitamin B-12, and L-carnitine. These products are not FDA-approved but are legally compounded by licensed pharmacies following eased federal restrictions. The company acknowledges limited clinical data on efficacy and plans personalized patient assessments and ongoing monitoring. Experts caution about safety risks and lack of rigorous testing, highlighting the need for careful medical oversight. Hims aims to expand offerings and provide patient support through telehealth services.

Hims & Hers Health Inc (HIMS) shares are trading at USD 17.80 on Pluang, showing a 1.42% increase in the last day. The stock has a market cap of $4.11 billion and a 52-week low of $14.52 as of Nov 18, 2026 21:22 WIB.

More News (HIMS)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App